Karen Briscoe

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 533 citations

Surgical Oncology, Breast Oncology, Medicine +7

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

Georgina V. Long, Jeffrey S. Weber, James Larkin et al. · JAMA Oncology · 2017 · 177 citations · Full text

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler et al. · The Lancet Oncology · 2023 · 175 citations

Urology, Oncology, Genitourinary Cancer +7

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations

Surgical Oncology, Malignant Pleural Mesothelioma, Medicine +7

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 157 citations

Medicine, Metronomic Therapy, Gynecology +8